Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305214 · ClinicalTrials.gov registry record · NA
MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 405
- Enrollment target
NCT00305214 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 405 participants.
The verdict
NCT00305214, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 405 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the usefulness of Microvolt T Wave Alternans (MTWA) testing of patients that have had a heart attack and have decreased pumping ability of the lower chamber of their heart. MTWA testing is a non-invasive test used to detect the likelihood of developing abnormally fast rhythms in the lower chambers of the heart. The objective of the study is to prove that if a patient has a positive MTWA test, they will be more likely to develop abnormally fast and dangerous rhythms in the lower chambers of the heart. The results of the study will help doctors to determine which patients would benefit the most from having an Implantable Cardioverter Defibrillator (ICD) implanted.
Interventions
- PROCEDURE T Wave Alternans Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305214
The ClinicalTrials.gov registry entry for NCT00305214 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T Wave Alternans Test is the first listed.
NCT00305214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305214 about?
NCT00305214 is a clinical study titled "MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients". The purpose of the study is to determine the usefulness of Microvolt T Wave Alternans (MTWA) testing of patients that have had a heart attack and have decreased pumping ability of the lower chamber of their heart. MTWA testing is a non-invasive test used to detect the likelihood of developing abnorm...
What is the current status of trial NCT00305214?
This trial is currently completed. It is a NA study. The enrollment target is 405 participants. The study started on 2003-10. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00305214?
The interventions under investigation include: T Wave Alternans Test (PROCEDURE).
Who is sponsoring clinical trial NCT00305214?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.